News for Alnylam Pharmaceuticals, Inc. (0HD2.L)

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a leading biopharmaceutical company specializing in RNA interference (RNAi) therapeutics, with four FDA-approved drugs for rare genetic diseases.

On July 21, 2025, Alnylam Pharmaceuticals (ALNY), a leading name in the biopharmaceutical sector, received significant attention from the analyst community. Tru

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Truist has begun covering Alnylam Pharmaceuticals (ALNY), assigning a Buy rating and establishing a price target of $385. A crucial catalyst for Alnylam's near-

Summary Alnylam Pharmaceuticals Inc (ALNY), a pioneer in RNA interference (RNAi) therapeutics, has announced that it will release its financial results for the

[url="]Alnylam Pharmaceuticals, Inc.[/url] (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the

On July 16, 2025, JP Morgan analyst Jessica Fye announced updates regarding Alnylam Pharmaceuticals (ALNY). The analyst has maintained an "Overweight" rating fo

JPMorgan analyst Jessica Fye has revised the price target for Alnylam (ALNY), raising it from $338 to $348 while maintaining an Overweight rating on the company

Morgan Stanley analyst Michael Ulz has revised the price target for Alnylam (ALNY) to $312, up from the previous target of $287. The analyst maintains an Equal

BridgeBio Pharma has had its stock price target increased by analysts at Leerink from $53 to $56, with the firm maintaining an Outperform rating. The company's

In recent developments, Citigroup has reaffirmed its

Bank of America (BofA) has increased its price target for Alnylam Pharmaceuticals (ALNY) from $336 to $359 while maintaining a Buy rating. This decision follows

Alnylam Pharmaceuticals (ALNY) saw its price target increased by Citi from $364 to $404, while maintaining a Buy rating for the stock. This adjustment comes as

Alnylam Pharmaceuticals (ALNY) received a bullish update from Jefferies on July 7, 2025. The investment banking firm has maintained its "Buy" rating for the com

[caption id=

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is among the best stocks added in a Growth Stock Portfolio. BMO Capital maintained an ‘Outperform’ rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), announcing this on June 24, 2025. The analyst raised its price target on the company’s stock from $300 to $360. BMO Capital attributed this update to a drastic increase […]

Needham has increased the price target for Alnylam (ALNY) from $320 to $377, maintaining a Buy rating on the stock. This decision follows a recent investor tour

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that Pushkal Garg, M.D., has been appoi

The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce reductions.